Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 216

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 216
---
     |               |       |   |     |               |       |   |
| Withdrawal from short term deposit                                          |     |               | 1,000 |   |     |               |     - |   |
| Purchase of property, plant and equipment                                   |     |               |     * | ) |     |               |     - |   |
| NET CASH PROVIDED BY INVESTING ACTIVITIES                                   |     |               | 1,000 |   |     |               |     - |   |
| INCREASE IN CASH AND CASH EQUIVALENTS                                       |     |               |   643 |   |     |               |  (148 | ) |
| CASH AND CASH EQUIVALENTS AT THE BEGINNING OF PERIOD                        |     |               | 3,268 |   |     |               | 1,186 |   |
| CASH AND CASH EQUIVALENTS AT THE END OF PERIOD                              |     |             $ | 3,911 |   |     |             $ | 1,038 |   |

| *) | less than 1 thousand |

<div align='center'>The accompanying notes are an integral part of
these financial statements.

F-38</div>

REVIUM RX.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands

NOTE 1:– GENERAL

On December
17, 2024, the Company completed the redomicile from the State of Delaware to the State of Nevada (the “Reincorporation. As a result
of the Reincorporation, the Company ceased its business existence as a Delaware corporation and continued its business existence as a
Nevada corporation under the name “Revium Rx.”

In November
2023, the Successor entered into a stock exchange agreement (“Share Exchange”) with Lipovation Ltd, a private Israeli company
engaged in the development of novel pharmaceutical solutions (“Lipovation” or the “Predecessor”). Following the closing
of such agreement on July 23, 2024, the Predecessor became a wholly owned subsidiary of the Company, and as determined by the Company’s
board of directors. Following the closing of the Share Exchange agreement, the Company’s Board of Directors determined to discontinue
all of the Company’s prior activities and efforts in the development and activation of the clinical decision-making support system
which constituted the business